{"id":"https://openalex.org/W4392691756","doi":"https://doi.org/10.1158/2326-6066.c.6548174","title":"Data from Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer","display_name":"Data from Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4392691756","doi":"https://doi.org/10.1158/2326-6066.c.6548174"},"language":"en","primary_location":{"id":"doi:10.1158/2326-6066.c.6548174","doi":"https://doi.org/10.1158/2326-6066.c.6548174","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548174","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/2326-6066.c.6548174","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079773324","display_name":"Lee P. Richman","orcid":"https://orcid.org/0000-0002-4601-5190","observed_orcids":["https://orcid.org/0000-0002-4601-5190"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lee P. Richman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5040750947","display_name":"Robert H. Vonderheide","orcid":"https://orcid.org/0000-0002-7252-954X","observed_orcids":["https://orcid.org/0000-0002-7252-954X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert H. Vonderheide","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fcgammariib","display_name":"Fc\u03b3RIIB","score":0.8569999933242798},{"id":"https://openalex.org/keywords/tnf-receptor-superfamily","display_name":"TNF receptor superfamily","score":0.7170000076293945},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.6169999837875366},{"id":"https://openalex.org/keywords/antigen-presenting-cell-activation","display_name":"antigen-presenting cell activation","score":0.8479999899864197},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.9120000004768372},{"id":"https://openalex.org/keywords/complement-dependent-cytotoxicity","display_name":"complement-dependent cytotoxicity","score":0.9850000143051147},{"id":"https://openalex.org/keywords/k562-cells","display_name":"K562 cells","score":0.6800000071525574},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.5460000038146973},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.9070000052452087}],"concepts":[{"id":"https://openalex.org/C187898756","wikidata":"https://www.wikidata.org/wiki/Q395324","display_name":"Agonistic behaviour","level":3,"score":0.8992408514022827},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.7090098857879639},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5631449818611145},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.512535572052002},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5013039112091064},{"id":"https://openalex.org/C163864487","wikidata":"https://www.wikidata.org/wiki/Q6901461","display_name":"Monoclonal","level":4,"score":0.4157482981681824},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.35091954469680786},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33611568808555603},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18396413326263428},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0},{"id":"https://openalex.org/C2779448149","wikidata":"https://www.wikidata.org/wiki/Q191797","display_name":"Aggression","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2326-6066.c.6548174","doi":"https://doi.org/10.1158/2326-6066.c.6548174","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548174","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2326-6066.c.6548174","doi":"https://doi.org/10.1158/2326-6066.c.6548174","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548174","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2169772944","https://openalex.org/W1970907457","https://openalex.org/W4255133931","https://openalex.org/W1982861708","https://openalex.org/W2055508595","https://openalex.org/W2411733041","https://openalex.org/W2547374683","https://openalex.org/W1632142035","https://openalex.org/W2887130186","https://openalex.org/W4404064450"],"abstract_inverted_index":{"Abstract":[0],"Agonists":[1],"of":[2,6,31,106,130,138,157,172,179,259],"the":[3,28,104,128,135,160,170,180,204,223,252,257,260],"TNF":[4,20],"superfamily":[5],"receptors":[7,21],"hold":[8],"promise":[9],"as":[10,24,152,188,201],"novel":[11],"therapy":[12],"for":[13,37,199,222,240],"cancer.":[14],"Recent":[15],"data":[16],"on":[17,112,251],"agonistic":[18,241],"antimurine":[19,107],"(TNFR)":[22],"such":[23,187],"CD40":[25,46,108,125,219,224,243,253],"suggest":[26],"that":[27,103,178],"specific":[29],"engagement":[30],"Fc":[32,233],"receptor":[33],"(FcR)":[34],"is":[35,55,66,72,235,248],"required":[36],"optimal":[38],"antitumor":[39],"effects,":[40],"prompting":[41],"calls":[42],"to":[43,74,177],"engineer":[44],"antihuman":[45,242],"and":[47,97,121,193,213,256],"other":[48,98],"TNFR":[49],"monoclonal":[50],"antibodies":[51],"(mAb)":[52],"accordingly.":[53],"CP-870,893":[54,81,158,182,200,229],"a":[56],"fully":[57],"human":[58,139],"anti-CD40":[59],"mAb,":[60],"selected":[61],"in":[62,85,92,118,169,215,245],"part":[63],"because":[64],"it":[65],"an":[67,153,165,237],"immunoglobulin":[68],"G2":[69],"(IgG2),":[70],"which":[71,209,246],"presumed":[73],"have":[75],"poor":[76],"reactivity":[77],"with":[78,89,94,145,203],"FcR;":[79],"however,":[80],"has":[82],"been":[83],"evaluated":[84],"multiple":[86],"clinical":[87],"trials":[88],"beneficial":[90],"activity":[91,105],"patients":[93],"melanoma,":[95],"pancreatic,":[96],"cancers.":[99],"Here,":[100],"we":[101],"confirmed":[102],"mAb":[109,126,207,220],"was":[110,115,142],"dependent":[111,250],"Fc\u03b3RIIB":[113],"engagement,":[114],"decreased":[116],"significantly":[117],"Fc\u03b3RIIB\u2212/\u2212":[119],"mice,":[120],"upon":[122],"Fc-crosslinking":[123],"antimouse":[124],"enhanced":[127,144],"activation":[129,137,174],"antigen-presenting":[131],"cells.":[132],"In":[133],"contrast,":[134],"CP-870,893-mediated":[136],"B":[140],"cells":[141,163],"not":[143,236],"anti-IgG":[146],"crosslinking":[147,234],"nor":[148],"abrogated":[149],"when":[150],"used":[151],"F(ab)\u20322":[154],"reagent.":[155],"Crosslinking":[156],"using":[159],"CD32-expressing":[161],"K562":[162],"yielded":[164],"Fc-dependent":[166,185],"modest":[167],"increase":[168],"expression":[171],"some":[173],"markers":[175],"relative":[176],"soluble":[181],"mAb.":[183],"Classic":[184],"functions":[186],"antibody-dependent":[189],"cellular":[190],"cytotoxicity":[191,195],"(ADCC)":[192],"complement-mediated":[194],"(CMC)":[196],"were":[197],"minimal":[198],"compared":[202],"IgG1":[205],"anti-CD20":[206],"rituximab,":[208],"mediated":[210],"both":[211],"ADCC":[212],"CMC":[214],"parallel":[216],"assays.":[217],"Antimouse":[218],"competed":[221],"ligand":[225],"binding":[226],"site,":[227],"but":[228],"did":[230],"not.":[231],"Thus,":[232],"essential":[238],"requirement":[239],"mAbs,":[244],"potency":[247],"more":[249],"epitope":[254],"recognized":[255],"strength":[258],"signal":[261],"achieved.":[262],"Cancer":[263],"Immunol":[264],"Res;":[265],"2(1);":[266],"19\u201326.":[267],"\u00a92013":[268],"AACR.":[269]},"counts_by_year":[],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2024-03-13T00:00:00"}